Measles-Rubella combined vaccine(MR)
ApprovedVaccine
Measles-Rubella combined vaccine(MR) is one of 20 biologic programs targeting Japanese encephalitis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Japanese Encephalitis
#DrugCompanyPhaseTrials
1Hepatitis a Vaccine
SanofiPhase 3
Prevnar
GSKPhase 3
Havrix
GSKPhase 3
Measles Vaccine
GSKPhase 3
Rituxan
RochePhase 2
Measles-Mumps-Rubella Vaccine
LLiaoning Chengda Biotechnology CO., LTD
Approved
Virazole
CConrado Roberto Hoffmann Filho
Phase 2
Varicella Vaccine
SanofiPhase 3
Immunoglobulin
SanofiPhase 2
Measles-Rubella combined vaccine(MR)
CCenters for Disease Control and Prevention, China
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details